Project description:Transcriptional profiling of ethanol tolerant strains Ets2 and Ets3 comparing control Saccharomyces cerevisiae L3262 with ethanol tolerant strains Ets2 and Ets3, through screening a mutant library of SPT15 of Saccharomyces cerevisiae L3262.
Project description:Transcriptional profiling of ethanol tolerant strains Ets2 and Ets3 comparing control Saccharomyces cerevisiae L3262 with ethanol tolerant strains Ets2 and Ets3, through screening a mutant library of SPT15 of Saccharomyces cerevisiae L3262. Four-condition experiment, L3262 vs. Ets2 or Ets3 strains. Biological replicates: 4 control, each 2 transfected(Ets2, Ets3), independently grown and harvested. One replicate per array.
Project description:Transcripitonal profiling of Saccharomyces cerevisiae treated with 2% n-alkanes vs untreatment Multiple condition experiment, S. cerevisiae treated with n-alkanes (n-nonane, n-decane, n-undecane, n-dodecane, respectively) for 24hrs or 48hrs, compared to control (those without treatment)
Project description:Investigation of whole genome gene expression level changes in three S. cerevisiae Y55 mutants, compared to the wild-type strain. The UV-induced mutations enable the mutant strains to ferment high-gravity maltose faster than the WT. The mutants analyzed in this study are further described in Baerends, R.J.S., J.L. Qiu, L. Gautier, and A. Brandt. A high-throughput system for screening of fast-fermenting Saccharomyces cerevisiae strains. Manuscript in preparation.
Project description:Saccharomyces cerevisiae has been used as a secretion host for production of various products, including pharmaceuticals. However, few antibody molecules have been functionally expressed in S. cerevisiae due to the incompatible surface glycosylation. Our laboratory previously isolated a group of yeast mutant strains with different α-amylase secretory capacities, and these evolved strains have showed advantages for production of some heterologous proteins. However, it is not known whether these secretory strains are generally suitable for pharmaceutical protein production. Here, three non-glycosylated antibody fragments with different configurations (Ran-Fab fragment Ranibizumab, Pex-the scFv peptide Pexelizumab, and Nan-a single V-type domain) were successfully expressed and secreted in three background strains with different secretory capacities, including HA (wild type), MA (evolved strain), and LA (evolved strain). However, the secretion of Ran and Nan were positively correlated with the strains’ secretory capacity, while Pex was most efficiently secreted in the parental strain. Therefore, transcriptional analysis was performed to explore the fundamental changes triggered by the expression of the different pharmaceutical proteins in these selected yeast strains.
